Gilead Sciences reported $256M in Interest Expense on Debt for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
Alexion Pharmaceuticals ALXN:US $ 27.1M 0.6M
ALKERMES ALKS:US 2.41M 537K
Alnylam Pharmaceuticals ALNY:US $ 33.42M 901K
Amgen AMGN:US $ 281M 4M
Arena Pharmaceuticals ARNA:US $ 1.05M 0.02M
Biogen BIIB:US $ 56.4M 8.3M
Biomarin Pharmaceutical BMRN:US $ 3.82M 0.01M
Bristol Myers Squibb BMY:US $ 330M 23M
Coherus Biosciences CHRS:US $ 5.75M 0.1M
Eli Lilly And LLY:US $ 86.9M 0.9M
Gilead Sciences GILD:US $ 256M 1M
Intercept Pharmaceuticals ICPT:US $ 12.59M 0.17M
Moderna Inc MRNA:US 5M 2M
Neurocrine Biosciences NBIX:US $ 6.2M 0.2M
Novartis NOVN:VX 201M 1000K
Pfizer PFE:US $ 316M 20M
Ptc Therapeutics PTCT:US $ 22.56M 2.7M
Puma Biotechnology PBYI:US $ 3.52M 0.07M
Regeneron Pharmaceuticals REGN:US $ 14.4M 0.2M
Sarepta Therapeutics SRPT:US $ 15.83M 0.18M
Teva Pharmaceutical Industries TEVA:US $ 240M 1M
United Therapeutics UTHR:US $ 4.7M 0.1M
Vertex Pharmaceuticals VRTX:US $ 15.48M 0.2M
YTE INCY:US $ 0.36M 0M